B. Riley last night initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target Opus is a clinical stage company developing simplified AAV gene augmentation therapies for ultra-rare inherited retinal diseases, the analyst tells investors in a research note. The firm believes multiple candidates from the company may achieve accelerated paths to approval due to favorable regulatory dynamics in ultra-rare ophthalmology. The Street has not yet appreciated this potential, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD: